Home > News By Company > WMR
Lysosomal Alpha Glucosidase Market - Size, Share, Outlook, and Forecast till 2026
Lysosomal Alpha Glucosidase Market, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years.
(EMAILWIRE.COM, September 28, 2018 ) Lysosomal alpha-glucosidase is an enzyme that is encoded by the GAA gene in humans. It is also called as α-1, 4-glucosidase and acid maltase. Any errors in this gene would lead to glycogen storage disease type II and Pompe disease. Acid alpha-glucosidase essential for the degradation of glycogen to glucose in lysosomes is encoded by this gene. By proteolytic processing, different forms of acid alpha-glucosidase can be obtained. Three transcript variants encoding the same protein have been found for this gene. Lysosomal alpha-glucosidase is used for the treatment of glycogen storage disease and Pompe disease.
Increasing prevalence of diseases such as glycogen storage disease and Pompe disease and increasing number of population are major factors driving growth of lysosomal alpha glucosidase market.
Download a Copy of Sample @ https://www.worldwidemarketreports.com/sample/196805
Key Developments in Lysosomal Alpha Glucosidase Market
Key players are adopting various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain its position in the lysosomal alpha glucosidase market. On March 22, 2018, Amicus Therapeutics announced that Japan's Ministry of Health, Labor and Welfare (MHLW) approved the oral small molecule pharmacological chaperone Galafold® capsules for the treatment of Fabry disease.
On February 27, 2018, Amicus Therapeutics launched Healing Beyond Disease™ initiatives to change lives of people living with rare diseases. Moreover, on April 30, 2018, the U.S. Food and Drug Administration (FDA) accepted priority review of cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery.
In June 2017, Sarepta Therapeutics signed a collaboration with Genethon, a non-profit R&D organization dedicated to the development of biotherapies for orphan genetic diseases from research to clinical validation. Furthermore, on April 26, 2018, JCR Pharmaceuticals announced the decision of the company to construct the Second Clinical Trial Material Manufacturing Center.
Some of the key players operating in the lysosomal alpha glucosidase market include Amicus Therapeutics Inc, Audentes Therapeutics Inc, Etubics Corp, Genzyme Corp, greenovation Biotech GmbH, Huons Co Ltd, JCR Pharmaceuticals Co Ltd, Oxyrane Belgium NV, Pharming Group NV, and Sarepta Therapeutics Inc among others.
Click Here For Discounts @ https://www.worldwidemarketreports.com/discount/196805
Table of Contents
1.Research Objective and assumption
2.Market Purview
3.Market Dynamics, Regulations, and Trends Analysis
4.Global Lysosomal Alpha Glucosidase Market, By Product Type, 2018–2026 (US$ Million)
5.Global Lysosomal Alpha Glucosidase Market, By Surgery, 2018–2026 (US$ Million)
6.Global Lysosomal Alpha Glucosidase Market, By Region, 2018–2026 (US$ Million )
7.Competitive Landscape
8.Section
Else, Speak to Analyst Before Buying @ https://www.worldwidemarketreports.com/speakanalyst/196805
Increasing prevalence of diseases such as glycogen storage disease and Pompe disease and increasing number of population are major factors driving growth of lysosomal alpha glucosidase market.
Download a Copy of Sample @ https://www.worldwidemarketreports.com/sample/196805
Key Developments in Lysosomal Alpha Glucosidase Market
Key players are adopting various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain its position in the lysosomal alpha glucosidase market. On March 22, 2018, Amicus Therapeutics announced that Japan's Ministry of Health, Labor and Welfare (MHLW) approved the oral small molecule pharmacological chaperone Galafold® capsules for the treatment of Fabry disease.
On February 27, 2018, Amicus Therapeutics launched Healing Beyond Disease™ initiatives to change lives of people living with rare diseases. Moreover, on April 30, 2018, the U.S. Food and Drug Administration (FDA) accepted priority review of cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery.
In June 2017, Sarepta Therapeutics signed a collaboration with Genethon, a non-profit R&D organization dedicated to the development of biotherapies for orphan genetic diseases from research to clinical validation. Furthermore, on April 26, 2018, JCR Pharmaceuticals announced the decision of the company to construct the Second Clinical Trial Material Manufacturing Center.
Some of the key players operating in the lysosomal alpha glucosidase market include Amicus Therapeutics Inc, Audentes Therapeutics Inc, Etubics Corp, Genzyme Corp, greenovation Biotech GmbH, Huons Co Ltd, JCR Pharmaceuticals Co Ltd, Oxyrane Belgium NV, Pharming Group NV, and Sarepta Therapeutics Inc among others.
Click Here For Discounts @ https://www.worldwidemarketreports.com/discount/196805
Table of Contents
1.Research Objective and assumption
2.Market Purview
3.Market Dynamics, Regulations, and Trends Analysis
4.Global Lysosomal Alpha Glucosidase Market, By Product Type, 2018–2026 (US$ Million)
5.Global Lysosomal Alpha Glucosidase Market, By Surgery, 2018–2026 (US$ Million)
6.Global Lysosomal Alpha Glucosidase Market, By Region, 2018–2026 (US$ Million )
7.Competitive Landscape
8.Section
Else, Speak to Analyst Before Buying @ https://www.worldwidemarketreports.com/speakanalyst/196805
Contact Information:
WMR
Mr. Shah
Tel: 8087996871
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
WMR
Mr. Shah
Tel: 8087996871
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results